Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of 3-week AT-1 receptor blockade on insulin resistance
2006-000490-29Phase 2Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of telmisartan in cardiometabolic risk (CMR), impaired glucose homeostasis and prehypertension, sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: Insulin effect in glucose metabolism. Started Feb 2006; status: completed.
02
Drugs
telmisartan
03
Conditions
cardiometabolic risk (CMR)impaired glucose homeostasisprehypertension
Beyond the preview
Go deeper on 2006-000490-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000490-29.